Polyclinic Váš Lekár enters clinical trials and significantly strengthens its investment profile

In recent months, Holding Váš Lekár has focused on streamlining its operations and developing its business, achieving several important milestones that are also significant for the investment opportunity, which you can still join. We will close the investment on January 30, 2026! Express your non-binding interest today.

Business expansion into clinical trials

After lengthy and demanding preparations and negotiations, clinical trials will be conducted at the Váš Lekár polyclinic in cooperation with an international pharmaceutical company. This is a milestone that significantly improves the clinic's profile – it brings a new, high-margin and stable source of income, strengthens the clinic's prestige, and increases its attractiveness to patients and partners alike.

Clinical trials also confirm the professionalism and expertise of the staff and represent an extraordinary success, especially given that the polyclinic has been in existence for less than 2 years. From the second quarter of 2026, clinical trials of drugs for metabolic diseases will begin at the polyclinic. This is the third phase of clinical trials, which means that the drugs being tested have already been proven to meet safety and efficacy criteria.

7 reasons why the move to clinical trials is positive news for investors and an opportunity for new investors to enter the market

External confirmation of the quality and credibility of the facility. Pharmaceutical companies enter into clinical partnerships exclusively with facilities that meet strict regulatory, professional, and operational standards. Such partnerships confirm that the facility has qualified personnel, infrastructure, and processes at the level of international clinical trials, thereby significantly reducing the reputational and operational risk of the investment.

Clinical trials generate stable and diversified revenues. Unlike conventional healthcare, clinical trials are funded directly by pharmaceutical partners, often under long-term contracts, creating predictable cash flow that is not dependent on public health insurance or political decisions.

The subject of testing are innovative new-generation drugs for the treatment of metabolic and chronic diseases, which are in high demand globally and have enormous market potential. This therapeutic segment has generated exceptionally high revenues in recent years and is one of the fastest growing areas of the pharmaceutical market. Participation in the development of such drugs means that the clinic is directly linked to one of the strongest trends in modern healthcare.

The possibility of co-ownership or capital participation in the clinic where these studies will be conducted. This offers investors not only a return on the operation of the facility, but also a share in a strategic asset whose value may grow along with the importance of clinical research and the expansion of the portfolio of drugs being tested.

This is an investment with significant growth potential. The success of drugs in this therapeutic class has already proven that properly targeted clinical research can generate billions in value. Being part of the infrastructure where such development takes place means being at the beginning of the value chain – where the greatest long-term potential lies.

The partnership creates a barrier to entry for competitors. Building a clinical facility capable of conducting advanced clinical trials is both time-consuming and regulatory-intensive. Investors can thus enter a project that has a competitive advantage.

Clinical trials significantly increase the valuation of a polyclinic in a future exit. Healthcare facilities involved in clinical research are significantly more attractive to strategic investors, funds, and global pharmaceutical groups than standard clinics, which increases the likelihood of a successful sale or additional capital inflow.

From an investor's perspective, this is therefore a strategic opportunity that combines the stability of the healthcare sector with the dynamism of innovative pharmaceutical research. The clinical trial partnership significantly increases the value of the facility, its future scalability, and its attractiveness to other partners. Investors should not overlook opportunities like this.

In addition, the company also underwent a management audit.

Peter Potúček, who has 20 years of experience in healthcare, both in commercial business at the international pharmaceutical company Novartis and as a member of the Management Board of the European Medicines Agency and Director of the State Institute for Drug Control, has been appointed as the new CEO. He is also a strategic consultant in the field of regulation and supervision of medicines, medical devices, and clinical trials.

*Investments involve the risk of partial or total loss of the money invested. Your investment is not covered by the deposit protection scheme.